Mitogen-activated protein kinase p38 pathway in venous ulcer fibroblasts

Vascular and Endovascular Surgery

Volumn 42, Issue 4, 2008, Pages 367-374

  Raffetto, Joseph D ^a,b,f   Gram, Christopher H ^c   Overman, Kristen C ^a,d   Menzoian, James O ^e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Surgical Specialists of Decatur   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

^f VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Cell proliferation; Fibroblasts; Growth factors; Kinase inhibitor; MAPK p38; Mitogen activated protein kinase; SB203580; Senescence; Venous ulcer

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PUNCH BIOPSY; ULCER; VEIN THROMBOSIS;

ADULT; AGED; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; HUMANS; IMIDAZOLES; INTERLEUKIN-1; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VARICOSE ULCER;

EID: 49649122103     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/1538574408316140     Document Type: Article

References (40)

1. Stanley AC, Park HY, Phillips TJ, Russakovsky V., Menzoian JO Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg. 1997 ; 26: 994-1001.
2. Mendez MV, Stanley A., Park HY, Shon K., Phillips T., Menzoian JO Fibroblasts cultured from venous ulcers display cellular characteristics of senescence. J Vasc Surg. 1998 ; 28: 876-883.
3. Ray LB, Sturgill TW Insulin-stimulated microtubuleassociated protein kinase is phosphorylated on tyrosine and threonine in vivo. Proc Natl Acad Sci USA. 1988 ; 85: 3753-3757.
4. Widmann C., Gibson S., Jarpe MB, Johnson GL Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev. 1999 ; 79: 143-180.
5. Force T., Bonventre JV Growth factors and mitogen-activated protein kinases. Hypertension. 1998 ; 31: 152-161.
6. Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem. 1996 ; 271: 24313-24316.
7. Mendez MV, Raffetto JD, Phillips TJ, Menzoian JO, Park HY The proliferative capacity of neonatal skin fibroblasts is reduced after exposure to venous ulcer fluid: a potential mechanism for senescence in venous ulcers. J Vasc Surg. 1999 ; 30: 734-743.
8. Raffetto JD, Vasquez R., Goodwin DG, Menzoian JO Mitogen activated protein kinase pathway regulates cell proliferation in venous ulcer fibroblasts. Vasc Endovasc Surg. 2006 ; 40: 59-66.
9. Eklöf B., Rutherford RB, Bergan JJ, et al. American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004 ; 40: 1248-1252.
10. Cuenda A., Rouse J., Doza YN, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995 ; 364: 229-233.
11. Kankaanranta H., De Souza PM, Barnes PJ, Salmon M., Giembycz MA, Lindsay MA SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther. 1999 ; 290: 621-628.
12. Park HY, Campisi, J. Posttranslational control of cyclic AMP-dependent protein kinase by phorbol ester in normal but not in chemically transformed 3T3 cells. Cancer Res. 1990 ; 50: 7145-7152.
13. Simpson IA, Soanne O. A simple, rapid, and sensitive method for measuring protein concentration in subcellular membrane fractions prepared by sucrose density ultracentrifugation. Anal Biochem. 1982 ; 119: 424-427.
14. Laemmli UK Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature. 1970 ; 227: 680-685.
15. Christopoulos D., Nicolaides AN, Szendro G. Venous reflux: quantification and correlation with the clinical severity of chronic venous disease. Br J Surg. 1988 ; 75: 352-356.
16. Raffetto JD, Khalil RA Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology. In press.
17. Eberhardt RT, Raffetto JD Contemporary review in cardiovascular medicine. Chronic venous insufficiency. Circulation. 2005 ; 111: 2398-2409.
18. Bergan JJ, Schmid-Shonbein GW, Coleridge Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med. 2006 ; 355: 488-498.
19. Burnand KG, Whimster I., Naidoo A., Browse NL Pericapillary fibrin in the ulcer-bearing skin of the leg: the cause of lipodermatosclerosis and venous ulceration. Br Med J. 1982 ; 285: 1071-1072.
20. Chen WY, Rogers AA Recent insights ino the causes of chronic leg ulceration in venous diseases and implications on other types of chronic wounds. Wound Repair Regen. 2007 ; 15: 434-449.
21. Pappas PJ, DeFouw DO, Venezio LM, et al. Morphometric assessment of the dermal microcirculation in patients with chronic venous insufficiency. J Vasc Surg. 1997 ; 26: 784-795.
22. Pappas PJ, You R., Rameshwar P., et al. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production. J Vasc Surg. 1999 ; 30: 1129-1145.
23. Stacey MC, Burnand KG, Bhogal BS, Black MM Pericapillary fibrin deposits and skin hypoxia precede the changes of lipodermatosclerosis in limbs at increased risk of developing a venous ulcer. Cardiovasc Surg. 2000 ; 8: 372-380.
24. Zamboni P., Scapoli G., Lanzara V., et al. Serum iron and matrix metalloproteinase-9 in limbs affected by chronic venous disease and venous leg ulcers. Dermatol Surg. 2005 ; 31: 644-649.
25. Bucalo B., Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen. 1993 ; 1: 181-186.
26. Wysocki AB, Staiano-Coico L., Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993 ; 101: 64-68.
27. Lal BK, Saito S., Pappas PJ, et al. Altered proliferative responses of dermal fibroblasts to TGF-beta1 may contribute to chronic venous stasis ulcer. J Vasc Surg. 2003 ; 37: 1285-1293.
28. Kim BC, Kim HT, Park SH, et al. Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression. J Cell Physiol. 2003 ; 195: 331-336.
29. Seidman C., Raffetto JD, Overman KC, Menzoian JO Venous ulcer fibroblasts respond to basic fibroblast growth factor at the cell cycle protein level. Ann Vasc Surg. 2006 ; 20: 376-380.
30. Park MT, Choi JA, Kim MJ, et al. Suppression of extracellular signal-related kinase and activation of p38 MAPK are two critical events leading to caspase-8- and mitochondria-mediated cell death in phytosphingosinetreated human cancer cells. J Biol Chem. 2003 ; 278: 50624-50634.
31. Perdiguero E., Ruiz-Bonilla V., Gresh L., et al. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J. 2007 ; 26: 1245-1256.
32. Lavoie JN, L'Allemain G., Brunet A., Müller R., Pouysségur J. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996 ; 271: 20608-20616.
33. Vasquez R., Marien BJ, Gram C., Goodwin DG, Menzoian JO, Raffetto JD Proliferative capacity of venous ulcer fibroblasts in the presence of platelet-derived growth factor. Vasc Endovascular Surg. 2004 ; 38: 355-360.
34. Turner NA, Ho S., Warburton P., O'Regan DJ, Porter KE Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. J Vasc Surg. 2007 ; 45: 1022-1028.
35. Seidman C., Raffetto JD, Marien B., Kroon C., Seah CC, Menzoian JO bFGF-induced alterations in cellular markers of senescence in growth rescued fibroblasts from chronic venous ulcer and venous reflux patients. Ann Vasc Surg. 2003 ; 17: 239-244.
36. Harris IR, Yee KC, Walters CE, et al. Cytokine and protease levels in healing and non-healing chronic venous leg ulcers. Exp Dermatol. 1995 ; 4: 342-349.
37. Phillips TJ, Al-Amoudi HO, Leverkus M., Park HY Effect of chronic wound fluid on fibroblasts. J Wound Care. 1998 ; 7: 527-532.
38. Wallace HJ, Stacey MC Levels of tumor necrosis factor-alpha (TNF-alpha) and soluble TNF receptors in chronic venous leg ulcers-correlations to healing status. J Invest Dermatol. 1998 ; 110: 292-296.
39. Trengove NJ, Bielefeldt-Ohmann H., Stacey MC Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen. 2000 ; 8: 13-25.
40. Cowin AJ, Hatzirodos N., Rigden J., Fitridge R., Belford DA Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound Repair Regen. 2006 ; 14: 421-426.